Studies related to Heart Rate and Ashwagandha

A Standardized Withania Somnifera Extract Significantly Reduces Stress-Related Parameters in Chronically Stressed Humans: A Double-Blind, Randomized, Placebo-Controlled Study
Effect Decrease
Values BMP. Placebo: before 78.4 (2.3), after 80.0 (3.4). 125 mg before 76.4 (4.6), after 71.8 (1.4). 250 mg before 80.7 (6.4), after 74.1 (3.7). 500 mg before 78.8 (7.7), after 73.6 (4.3)
Trial Design randomized
Trial Length 16months
Number of Subjects 130
Gender mixed
Notes for this study:
In a randomized, double-blind, placebo-controlled trial, 130 participants with an anxiety disorder were assigned to take 125 mg, 250 mg, or 500 mg of ashwagandha extract containing a minimum of 8% withanolide glycosides, 32% oligosaccharides, and a maximum of 2% withaferin A for 60 days. 32 participants dropped out, with more dropouts in the placebo group. While the placebo group saw no notable changes, the ashwaganda groups all saw statistically significant improvements compared with the placebo group in stress/anxiety, fatigue, flushing, perspiration, loss of appetite, headache and muscle pain, feelings of impending doom, palpitations, dry mouth, sleeplessness, forgetfulness, irritability, and inability to concentrate. The 250 mg and 500 mg groups seemed to be somewhat more potent than the 125 mg group for stress/anxiety, fatigue and inability to concentrate. Serum cortisol, CRP and serum VLDL-C, and blood pressure were statistically significantly reduced compared with placebo in all ashwagandha groups, and DHEAS was significantly increased. Fasting blood glucose, total serum cholesterol, serum triglycerides, LDL-C, and HDL-C were improved in the 250 mg and 500 mg groups compared with placebo, and the 500 mg group was significantly lower than the 125 mg group for all but CRP and fasting blood glucose.
Funding issues for this study:
"We would like to thank Natreon Inc. (New Brunswick, New Jersey) for financial support of this study. " "Dr. Auddy is an employee of Natreon Inc., which is the patent holder of Withania somnifera extract sold under the trade names Essentra® and Sensoril®. Dr. Abedon is an employee of NutraGenesis LLC, which sells Withania somnifera extract exclusively under the trade names Essentra® and Sensoril®. Dr. Ghosal was an unpaid adviser to Natreon Inc. at the time the study was conducted."

Body Weight Management In Adults Under Chronic Stress Through Treatment With Ashwagandha Root Extract: A Double-Blind, Randomized, Placebo-Controlled Trial

Effect None
Values BPM. Placebo: −2.08 (4.67). Ashwagandha −1.76 (4.70)
Trial Design Randomized trial
Trial Length 1-6 months
Number of Subjects 52
Gender Both Genders
Age Range 18-29, 30-44, 45-64
Body Types Obese, Overweight
Notes for this study:
In a randomized, double-blind, placebo-controlled trial, 52 stressed, overweight/obese participants were assigned to take placebo or 600 mg of an ashwagandha extract containing 5% withanolides for 8 weeks.

The primary outcomes were ratings on the Perceived Stress Scale and the Food Cravings Questionnaire-Trait. Compared with the placebo group, the ashwagandha group saw a statistically significant reduction in stress and some but not most components of the food cravings questionnaire, though all components saw a reduction. The Oxford Happiness Questionnaire score revealed a small, statistically significant improvement compared with placebo.

Cortisol was statistically significantly reduced in the ashwagandha group and so was body weight and BMI.